Emerging cell types are broadening the treatment scope of cell therapy, while automation, PAT and strategic partnerships are addressing manufacturing challenges. Emphasizing the safety of these therapies will improve accessibility and build patient trust, ultimately enhancing the impact of CAR-T cell therapies in the fight against cancer and other diseases.
Wednesday, September 09, 2026
Cell expansion has evolved from a necessary manufacturing step into one of the defining challenges of modern cell therapy, sitting at the intersection of biology, engineering, manufacturing and quality. As the field expands into new indications and larger patient populations, overcoming this challenge will be essential to improving scalability, reducing costs, and ensuring consistent product quality.